Bosulif 100 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DB25FSGEY
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,113
Award facts
- Contract value 100% obligated
- $17,113.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Bosulif 100 mg tablets (120-count units) with a contract ceiling value of $17,113.35. This firm fixed-price delivery order represents a non-competitive set-aside and is scheduled for ultimate completion by October 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999.99 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
Bosulif (bosutinib) is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, making this delivery order part of the Defense Logistics Agency's broader mission to ensure consistent pharmaceutical supply to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The non-set-aside competitive award reflects AmerisourceBergen Drug Corp's demonstrated capability to meet federal procurement requirements and aligns with the agency's strategy of leveraging established prime vendor contracts to deliver specialized oncology medications and critical medical commodities to support military personnel and veteran healthcare needs.
Quick answers
Who was awarded contract SPE2DB25FSGEY?
SPE2DB25FSGEY was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 29, 2025.
How much is contract SPE2DB25FSGEY worth?
The government has obligated $17,113 on SPE2DB25FSGEY.
Is contract SPE2DB25FSGEY an order under another contract?
Yes. SPE2DB25FSGEY is a delivery order under SPE2DB22D2211, an indefinite delivery contract.
Was contract SPE2DB25FSGEY competed?
The extent of competition for SPE2DB25FSGEY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award